Login  |  Register

Poxels Novel Anti diabetic Agent Imeglimin Meets …

Poxel’s Novel Anti-diabetic Agent Imeglimin Meets Glycemic Endpoints in Phase 2b Dose-Ranging Trial

Alexa Traffic


Listing Links